relapsing remitting multiple sclerosis
Showing 1 - 25 of 111
Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)
Not yet recruiting
- Relapsing Remitting Multiple Sclerosis
- PIPE-307 Dose A
- +2 more
- (no location specified)
Oct 9, 2023
Bafiertam Treatment In Routine Clinical Practice
Enrolling by invitation
- Relapsing Remitting Multiple Sclerosis
- Monomethyl Fumarate
-
West Hollywood, California
- +1 more
Aug 3, 2023
Integrated Digital Solutions in Medical Care of Multiple
Not yet recruiting
- Relapsing Remitting Multiple Sclerosis
- MS Care Platform (icobrain ms and icompanion ms)
- (no location specified)
Jul 10, 2023
Visual Processing Speed and Objective Analysis of Ocular
Enrolling by invitation
- Multiple Sclerosis
- +3 more
- Eye tracking
- +3 more
-
Valladolid, SpainIOBA - Universidad de Valladolid
Jan 20, 2023
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United
Recruiting
- Relapsing Multiple Sclerosis
- +2 more
- Autologous Hematopoietic Stem Cell Transplantation
- Best Available Therapy (BAT)
-
Palo Alto, California
- +20 more
Jan 25, 2023
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Birmingham, Saint Louis (Glycemic
Not yet recruiting
- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Glycemic load
- +2 more
-
Birmingham, Alabama
- +1 more
Jan 4, 2023
Relapsing Remitting Multiple Sclerosis Trial (monomethyl fumarate 190 mg, dimethyl fumarate 240 mg)
Completed
- Relapsing Remitting Multiple Sclerosis
- monomethyl fumarate 190 mg
- dimethyl fumarate 240 mg
- (no location specified)
Dec 5, 2022
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis Trial in United States (ANK-700, Placebo)
Recruiting
- Multiple Sclerosis (MS)
- Relapsing Remitting Multiple Sclerosis
- ANK-700
- Placebo
-
Cullman, Alabama
- +14 more
Dec 13, 2022
Upper Extremity Function in Multiple Sclerosis Advanced
Active, not recruiting
- Multiple Sclerosis
- +7 more
-
Tampa, FloridaCarol and Frank Morsani Center for Advanced Healthcare
Nov 2, 2022
Lesion Load and Location in Relation to Cognition, Fatigue and
Completed
- Relapsing Remitting Multiple Sclerosis
- VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
- Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
-
Assiut, EgyptEman Khedr
Oct 27, 2022
Relapsing Remitting Multiple Sclerosis Trial in United States (Vitamin D3)
Completed
- Relapsing Remitting Multiple Sclerosis
- Vitamin D3
-
Carmichael, California
- +15 more
Sep 12, 2022
Implementation ofNovel Functional Eye-Tracking Biomarker for
Recruiting
- Clinically Isolated Syndrome
- Relapsing Remitting Multiple Sclerosis
- Eye-tracking
-
Montréal, Quebec, CanadaMontreal Neurological Institute and Hospital
Sep 2, 2022
Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- Ublituximab
-
Pasadena, California
- +7 more
Aug 19, 2022
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination Trial in Australia, Canada, United
Terminated
- Relapsing Remitting Multiple Sclerosis
- +2 more
- CNM-Au8
- Placebo
-
Dallas, Texas
- +6 more
Aug 10, 2022
Mechanistic Studies of Teriflunomide in RRMS
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
-
Ann Arbor, MichiganUniversity of Michigan
Jul 27, 2022
Relapsing Remitting Multiple Sclerosis Trial in Glasgow (Clinical assessment)
Enrolling by invitation
- Relapsing Remitting Multiple Sclerosis
- Clinical assessment
-
Glasgow, United KingdomClinical Research Facility
Jul 20, 2022
Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)
Terminated
- Relapsing Remitting Multiple Sclerosis
- Pleneva TM BGC20-0134
- Placebo
-
Gent, Belgium
- +34 more
Jun 2, 2022
Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- 3 mg Melatonin
- 5 mg Melatonin
-
Portland, OregonProvidence MS Center
May 5, 2022
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial
Recruiting
- Relapsing Remitting Multiple Sclerosis
- +2 more
- Rituximab
- +4 more
-
Glostrup, Copenhagen, Denmark
- +11 more
May 3, 2022
Exercise on Contactin-1 and Contactin-2 Level in Persons With
Completed
- Relapsing Remitting Multiple Sclerosis
-
Elazığ, TurkeyFırat university
Apr 22, 2022
Relapsing Remitting Multiple Sclerosis Trial in Saint Louis (Intermittent fasting)
Completed
- Relapsing Remitting Multiple Sclerosis
- Intermittent fasting
-
Saint Louis, MissouriWashington University in St Louis
Apr 25, 2022
Tysabri in Early Relapsing Remitting Multiple Sclerosis
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
-
Amadora, Portugal
- +17 more
Apr 12, 2022
Relapsing Remitting Multiple Sclerosis Trial in Worldwide (alemtuzumab GZ402673)
Completed
- Relapsing Remitting Multiple Sclerosis
- alemtuzumab GZ402673
-
Cullman, Alabama
- +130 more
Mar 21, 2022
Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)
Recruiting
- Relapsing Remitting Multiple Sclerosis
-
Bergen, Norway
- +10 more
Mar 18, 2022
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Caen (Cognitive rehabilitation,
Recruiting
- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Cognitive rehabilitation
- Standard Psychological care
-
Caen, Calvados, FranceUniversity Hospital of Caen
Mar 8, 2022